Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 13, Number 3—March 2007

Worldwide Emergence of Extensively Drug-resistant Tuberculosis

N. Sarita Shah*1Comments to Author , Abigail Wright†, Gill-Han Bai‡2, Lucia Barrera§2, Fadila Boulahbal¶2, Nuria Martín-Casabona#2, Francis Drobniewski**2, Chris Gilpin††2, Marta Havelkovᇇ2, Rosario Lepe§§2, Richard Lumb¶¶2, Beverly Metchock*2, Françoise Portaels##2, Maria Filomena Rodrigues***2, Sabine Rüsch-Gerdes†††2, Armand Van Deun##2, Veronique Vincent‡‡‡2, Kayla F. Laserson*, Charles Wells*, and J. Peter Cegielski*
Author affiliations: *Centers for Disease Control and Prevention, Atlanta, Georgia, USA; †World Health Organization, Geneva, Switzerland; ‡Korean Institute of Tuberculosis, Seoul, Republic of Korea; §National Institute of Infectious Diseases, Buenos Aires, Argentina; ¶Institut Pasteur d’Algérie, Alger, Algeria; #Hospital Universitaris Vall d’Hebron, Barcelona, Spain; **Health Protection Agency, London, United Kingdom; ††Prince Charles Hospital, Brisbane, Queensland, Australia; ‡‡National Institute of Public Health, Scrobarova, Czech Republic; §§Institute of Public Health of Chile, Providencia Santiago, Chile; ¶¶Institute of Medical and Veterinary Science, Adelaide, South Australia, Australia; ##Institute of Tropical Medicine, Antwerp, Belgium; ***National Institute of Health, Porto, Portugal; †††National Reference Center for Mycobacteria, Borstel, Germany; ‡‡‡Institut Pasteur, Paris, France; 1Current affiliation: Albert Einstein College of Medicine, Bronx, New York, USA; 2Member: World Health Organization/International Union against Tuberculosis and Lung Diseases Network of Supranational Reference Laboratories

Main Article

Table 3

Second-line–drug resistance patterns for multidrug-resistant Mycobacterium tuberculosis isolates, 2000–2004*†‡

PatternNo. testedNo. (%) resistant
Any resistance (total)3,5201,542 (43.8)
Aminoglycosides (AG)§3,442630 (18.3)
Capreomycin (CM)2,743279 (10.2)
Fluoroquinolones (FQ)3,492673 (19.3)
Thioamides (TA)3,132605 (19.3)
Cycloserine (CS)2,615141 (5.4)
Para-aminosalicylic acid (PAS)2,860450 (15.7)
Extensively drug-resistant TB (XDR-TB, total)¶3,520347 (9.9)
AG + CM + FQ2,65690 (3.4)
AG + CM + TA2,49877 (3.1)
CM + FQ + TA26050 (19.2)
AG + FQ + TA3,040102 (3.4)
AG + FQ + CS13939 (28.1)
FQ + TA + PAS2,50594 (3.8)

*Tested for ≥3 second-line drug classes; SRLs, Supranational Reference Laboratories.
†Not all isolates were tested for each second-line drug class (with the exception of the Republic of Korea SRL), so results are reported as a proportion of isolates tested to the specified class of drugs. For combination resistance patterns, results are reported as a proportion of isolates tested to all of the classes of drugs in the specific combination.
‡Cells are not mutually exclusive.
§Other than streptomycin (e.g., kanamycin, amikacin).
¶XDR-TB, extensively drug-resistant tuberculosis, i.e., multidrug-resistant tuberculosis (resistant to at least isoniazid and rifampin) with additional resistance to ≥3 classes of second-line drugs.

Main Article

Page created: October 29, 2010
Page updated: October 29, 2010
Page reviewed: October 29, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.